USPH Q2 Revenue Rises 8.5% to $214M, Reaffirms Full-Year Outlook
USPH sits 34% above its 52-week low of $58.19.
Summary
U.S. Physical Therapy reported Q2 2026 revenue of $214.1 million, an 8.5% increase year-over-year, driven by higher patient visits and revenue per visit. GAAP EPS fell to $0.25 from $0.58 a year ago, largely due to dilution from redeemable noncontrolling interests as partner clinic values rose. Non-GAAP operating results per share were $0.75 versus $0.81, and adjusted EBITDA edged up to $27.0 million from $26.9 million. The company reaffirmed its full-year guidance and highlighted the completion of 31 hospital-affiliated clinic integrations, with 39 more expected in Q3, which management says will boost margins. This follows a Q1 loss driven by non-cash charges and the recent acquisition of a 12-clinic practice. The reaffirmed guidance and integration progress provide a steady outlook, but the GAAP EPS decline and margin pressure from health benefit costs warrant attention.
At the time of this announcement, USPH was trading at $77.71 on NYSE in the Trade & Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $58.19 to $93.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.